Figure 5: Comparison of the oncolytic efficacy of the EGFR retargeted viruses in the EGFR positive ovarian cancer tumor model.

(A) MV^EGFR and MV^CDVenvEGFR have similar oncolytic efficacy in a subcutaneous tumor model. Tumor volumes of subcutaneously implanted SKOV3i.p.1-Fluc cells treated with 6 intratumoral doses of 2 X 10⁶ TCID₅₀ of the respective viruses or control (producer Vero-⍺His lysate). (B-D) MV^EGFR and MV^CDVenvEGFR have similar oncolytic efficacy in an orthotopic, intra peritoneal model. (B) Serial bioluminescent imaging on the indicated days to monitor tumor burden of mice with i.p. SKOV3i.p.1-Fluc tumors treated with 2 X 10⁶ TCID₅₀ of indicated virus treatment or control (n=5 per group) 10 days post tumor implantation. (C) Quantification of total body luminescence (tumor burden) on day 14 post treatment; error bars indicate SEM. (D) Overall survival of treated animals. ns= not significant; *p<0.05